Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1954 2
1955 1
1956 1
1957 1
1958 1
1961 1
1963 2
1964 5
1965 4
1966 2
1967 5
1968 5
1969 3
1970 5
1971 6
1972 8
1973 5
1974 7
1975 28
1976 33
1977 30
1978 19
1979 22
1980 27
1981 40
1982 50
1983 44
1984 47
1985 85
1986 55
1987 58
1988 58
1989 82
1990 82
1991 100
1992 76
1993 95
1994 94
1995 117
1996 119
1997 125
1998 122
1999 136
2000 127
2001 162
2002 161
2003 176
2004 196
2005 215
2006 221
2007 237
2008 219
2009 265
2010 312
2011 351
2012 377
2013 407
2014 460
2015 427
2016 453
2017 464
2018 486
2019 527
2020 627
2021 621
2022 618
2023 637
2024 270

Text availability

Article attribute

Article type

Publication date

Search Results

9,513 results

Results by year

Filters applied: . Clear all
Page 1
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall'Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P. D'Agostino M, et al. J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605179 Free article.
PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model. ...PATIE …
PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are …
Review of 1027 patients with newly diagnosed multiple myeloma.
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Kyle RA, et al. Mayo Clin Proc. 2003 Jan;78(1):21-33. doi: 10.4065/78.1.21. Mayo Clin Proc. 2003. PMID: 12528874
OBJECTIVE: To determine the clinical and laboratory features of newly diagnosed multiple myeloma. PATIENTS AND METHODS: Records of all patients in whom multiple myeloma was initially diagnosed at the Mayo Clinic in Rochester, Minn, from January 1, 1985 …
OBJECTIVE: To determine the clinical and laboratory features of newly diagnosed multiple myeloma. PATIENTS AND METHODS: Record …
International staging system for multiple myeloma.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. Greipp PR, et al. J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4. J Clin Oncol. 2005. PMID: 15809451
PURPOSE: There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification. ...RESULTS: Serum beta2-microglobulin (Sbeta2M), serum albumin, platelet count, serum creatinine, a …
PURPOSE: There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for pa …
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley DC, Keller J, Thomas T, Carson KR, Gage BF. Sanfilippo KM, et al. Am J Hematol. 2019 Nov;94(11):1176-1184. doi: 10.1002/ajh.25603. Epub 2019 Aug 19. Am J Hematol. 2019. PMID: 31379000 Free PMC article.
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-risk of VTE …
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The Inter …
Multiple myeloma and physical activity.
Lecat CSY, McCourt O, Land J, Yong K, Fisher A. Lecat CSY, et al. BMC Res Notes. 2021 May 7;14(1):171. doi: 10.1186/s13104-021-05591-y. BMC Res Notes. 2021. PMID: 33962674 Free PMC article.
OBJECTIVE: Physical activity has been shown to improve quality of life in cancer patients with some evidence in multiple myeloma. This study aimed to determine myeloma patients' exercise levels, their perception of physical activity, and to explore correlations with …
OBJECTIVE: Physical activity has been shown to improve quality of life in cancer patients with some evidence in multiple myeloma …
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
Covut F, Ahmed R, Chawla S, Ricaurte F, Samaras CJ, Anwer F, Garcia AVM, Angelini DE, Mazzoni S, Faiman B, Valent J, Khouri J. Covut F, et al. Br J Haematol. 2021 Jun;193(6):1213-1219. doi: 10.1111/bjh.17505. Epub 2021 May 17. Br J Haematol. 2021. PMID: 33997961 Clinical Trial.
The IMPEDE VTE score has recently emerged as a novel risk prediction tool for venous thromboembolism (VTE) in multiple myeloma (MM). We retrospectively reviewed 839 patients with newly diagnosed MM between 2010 and 2015 at Cleveland Clinic and included …
The IMPEDE VTE score has recently emerged as a novel risk prediction tool for venous thromboembolism (VTE) in multiple …
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J. Facon T, et al. Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19. Leukemia. 2020. PMID: 31427722 Free PMC article. Clinical Trial.
Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment. Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investiga …
Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of tre …
Understanding high-risk smoldering multiple myeloma.
Kreiniz N, Gertz MA. Kreiniz N, et al. Leuk Lymphoma. 2023 Jul-Aug;64(8):1361-1372. doi: 10.1080/10428194.2023.2216818. Epub 2023 May 25. Leuk Lymphoma. 2023. PMID: 37229535 Review.
Smoldering multiple myeloma (SMM) is an asymptomatic condition with heterogeneous biology and various risks of progression to symptomatic disease. ...New markers of SMM progression, including genomic and immune characteristics of plasma cells (PCs) and tumor microen …
Smoldering multiple myeloma (SMM) is an asymptomatic condition with heterogeneous biology and various risks of progression to …
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Palumbo A, et al. Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27. Blood. 2015. PMID: 25628469 Free PMC article.
At diagnosis, a geriatric assessment had been performed. An additive scoring system (range 0-5), based on age, comorbidities, and cognitive and physical conditions, was developed to identify 3 groups: fit (score = 0, 39%), intermediate fitness (score = …
At diagnosis, a geriatric assessment had been performed. An additive scoring system (range 0-5), based on age, comorbidities, …
Comparing neuropathy in multiple myeloma and AL amyloidosis.
Ballegaard M, Nelson LM, Gimsing P. Ballegaard M, et al. J Peripher Nerv Syst. 2021 Mar;26(1):75-82. doi: 10.1111/jns.12428. Epub 2021 Jan 10. J Peripher Nerv Syst. 2021. PMID: 33368817
We compared clinical and laboratory results between two diagnostic groups. We recruited 76 untreated multiple myeloma (MM) and 27 AL amyloidosis (ALA) patients for evaluation of symptoms, clinical findings and nerve conduction studies (NCS). We diagnosed significant …
We compared clinical and laboratory results between two diagnostic groups. We recruited 76 untreated multiple myeloma (MM) and …
9,513 results